J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
Volkswagen CEO Urges Germany to Adopt China's Industrial Discipline Amid Major Restructuring 
Virgin Australia Adjusts Fares Amid Rising Aviation Costs and Middle East Tensions 
Elliott Investment Management Takes Activist Stake in Align Technology 
OpenAI's Desktop Superapp: Unifying ChatGPT, Codex, and Browser Tools for Enterprise AI 
Netflix Eyes South Korea for More Live Events as BTS Concert Livestream Approaches 
Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Sinopec Posts 36.8% Net Profit Drop in 2025 Amid Weak Petrochemical Margins and Energy Transition Pressures 
Apple Defies China's Smartphone Slump with Strong Early 2026 Sales 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security 
Xiaomi's AI Model "Hunter Alpha" Mistaken for DeepSeek's Next Release 
FCC Approves $3.54B Nexstar-Tegna Merger, Waiving Broadcast Ownership Cap 
Goldman Sachs Raises Oil Price Forecasts Amid Strait of Hormuz Disruptions 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
